SanBio Co ( (JP:4592) ) has provided an update.
SanBio Co., Ltd. has revised its consolidated earnings forecast for the fiscal year ending January 2025, reflecting expected foreign exchange gains of approximately 623 million yen. This adjustment is due to changes in exchange rates impacting foreign currency denominated loans and receivables, which will result in a negative adjustment in comprehensive income, highlighting the company’s exposure to currency fluctuations and its impact on financial performance.
More about SanBio Co
SanBio Co., Ltd. operates in the biotechnology industry, primarily focusing on regenerative cell therapies and innovative medical treatments. The company is known for its research and development of therapies targeting neurological disorders, aiming to address unmet medical needs in this specialized market.
YTD Price Performance: 0%
Average Trading Volume: 1,635
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $328M
See more insights into 4592 stock on TipRanks’ Stock Analysis page.